Agents for the treatment of viral infections

Details Agents for the treatment of viral infections Agents for the treatment of viral infections

A - Human Necessities

61

K

A61K 38/58 (2006.01) A61K 31/00 (2006.01) A61K 31/166 (2006.01) A61K 31/336 (2006.01) A61K 31/365 (2006.01) A61K 31/4015 (2006.01) A61K 31/407 (2006.01) A61K 31/415 (2006.01) A61K 31/47 (2006.01) A61K 31/5375 (2006.01) A61K 31/704 (2006.01) A61K 38/04 (2006.01) A61K 38/05 (2006.01) A61K 38/06 (2006.01) A61K 38/07 (2006.01) A61K 38/55 (2006.01) A61K 48/00 (2006.01) A61P 1/16 (2006.01) A61P 25/28 (2006.01) A61P 31/12 (2006.01) A61P 31/14 (2006.01) A61P 31/18 (2006.01) A61P 31/20 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2425632

The invention relates to agents for the treatment of viral infections, in particular, infections with hepatitis and retro-viruses. Said agents inhibit the release, maturation and replication of both retro-viruses and also hepatitis viruses. In the example of human immune deficiency virus (HIV) and hepatitis-B viruses it has been shown that proteasome inhibitors block the release of virus particles and the infectiousness of the released viral particles and thus the reproduction of the viruses. The proteasome ihibitors affect the activities in the ubiquitin/proteasome pathway, in particular the enzymatic activities of the 26S and the 20S proteasome complexes. The application for the above invention lies in anti-retroviral therapy, particularly the treatment of HIV infections and AIDS and in the anti-viral therapy of hepatitis infections, in particular the treatment of acute and chronic HBV and HCV infections and the associated liver carcinomas.

L'invention concerne des moyens pour le traitement d'infections à des virus, en particulier des infections aux virus de l'hépatite et rétrovirus. Cette invention concerne également des moyens pour empêcher la libération, la maturation et la réplication de rétrovirus et des virus de l'hépatite. Sur l'exemple des virus de l'immunodéficience humaine (VIH) et des virus de l'hépatite B, il a été démontré que des inhibiteurs du protéasome bloquent la libération de particules virales ainsi que l'infectivité des particules virales libérées et la multiplication du virus. Ces inhibiteurs du protéasome influencent les activités de la voie ubiquitine/protéasome, en particulier les activités enzymatiques des complexes du proséatome 26S et 20S. La présente invention trouve son application dans la thérapie antirétrovirale, en particulier dans le traitement d'infections au VIH et du SIDA, ainsi que dans la thérapie antivirale d'infections à l'hépatite, notamment le traitement d'infections aux virus de l'hépatite B et C aiguës et chroniques et de carcinomes du foie associés.

Affiliated with

Also associated with

Rating

Agents for the treatment of viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agents for the treatment of viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents for the treatment of viral infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1883237